The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
AM23-MN-08-O: Release Criteria for Cellular Therapy Products (CTPs) Prior to Distribution: Practical Advices That You Need to Know (Enduring)
Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)
$30$30.00
Standard Price
Members save $5
This program encompasses the different perspectives from two facilities (an institution that provides GMP laboratory and manufacturing services to multiple sponsors and researchers and an academic hospital-based processing laboratory). Release testing before distribution is an important requirement ensuring patients' safety treated with cellular tissue-based products. The quality and value of these tests can be affected by many factors, including validation of tests and staff training and proficiency. Description of tests and quality control required before release and distribution either for further manufacturing or as a final (finished) product for the administration of human cellular tissue-based products (HCTPs), both minimally manipulated and more than minimal manipulation (361 and 351 type products) will be discussed in this session.
Learning Objectives
Describe the different laboratory tests commonly used for the release of HCTPs (both 361 and 351 products).
Compare common laboratory tests between the different products.
Identify regulatory requirements for release criteria.
Evaluate different techniques and implementation procedures as well as lot to lot comparison, when appropriate.
All relevant financial relationships have been mitigated.
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
Credits Available
Purchasing this session will automatically provide ownership of all the individually purchasable attached CE products, regardless of their stated individual purchase restrictions.
AM23-MN-08-O: Release Criteria for Cellular Therapy Products (CTPs) Prior to Distribution: Practical Advices That You Need to Know (Enduring) Evaluation
Currently, six FDA-approved CAR-T cell therapies are available to patients, and at least two gene therapies for the treatment of rare and prevalent conditions…
Join us for an essential panel discussion on cybersecurity in healthcare, where real-world insights and expert analysis come together to enhance your organization's defenses. This session features three distinguished speakers from hospitals and blood centers that have faced cybersecurity attacks…
Session Description: Alloantibodies to RBCs, induced by transfusion and/or pregnancy, remain a clinical barrier to safe and effective transfusion and cause hemolytic disease of the fetus and new born (HDFN)…